Press Enter to search · ESC to close

US Stocks

Sanofi weighs acquisition of US drugmaker Insmed

Sanofi is considering an acquisition of US drugmaker Insmed and has hired advisers to assess the deal, which would be one of the largest biopharma M&A transactions in recent years. Insmed shares have fallen about 40% over the past 12 months, leaving it with a market value of roughly $26.6 billion. Sanofi’s shares are down 2.4% over the same period, giving the Paris-based group a market capitalization of €101.3 billion ($111.3 billion).

Original source

AI take

Sanofi exploring a deal for Insmed signals large-cap pharma's appetite for external growth is intact even as both stocks have lagged, and the disclosed adviser mandate suggests this is more than casual interest. The read-through lands on biotech M&A generally: a depressed Insmed valuation gives a cash-rich buyer a cheaper entry point, which matters for mid-cap biotech holders watching for similar takeout interest. Whether talks advance to a firm offer, and how Sanofi's own shareholders react to the capital commitment, is the open question.

Generated by AI for reference only.

Share

Related News

TREE NEWS share card
Long-press image above → Save to Photos / Share
Pitch us Feedback